Testing the addition of an anti-cancer drug, cabozantinib to the immunotherapy drug cemiplimab (REGN2810) , in adolescents and adults with advanced adrenocortical cancer

Full Title

A Phase II Study of Cabozantinib in Combination with Cemiplimab (REGN2810) (Cabo-Cemiplimab (REGN-2810)) Versus Cabozantinib Alone in Adolescents and Adults with Advanced Adrenocortical Cancer (A092204) (CIRB)

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Nitya Raj’s office at 646-888-4849.